Toxicidad pulmonar asociada a inmunoterapia con Nivolumab : presentación de un caso.
Toxicidad pulmonar asociada a inmunoterapia con Nivolumab : presentación de un caso.
Contenido principal del artículo
Resumen
Descargas
Detalles del artículo
Referencias (VER)
Nishino M, Ramaiya NH, Awad MM, Sholl LM4, Maattala JA, Taibi M, Hatabu H, Ott PA, Armand PF HF. PD-1 inhibitor-related pneumonitis in advanced cancer. Clin Cancer Res [Internet]. 2016;22(24):6051–60. Available from : https://www.ncbi.nlm.nih.gov/pubmed/27535979
Nishino M, Giobb ie-Hurder A, Hatabu H, Ramaiya NH, Hodi FS. Incidence of programmed cell death 1 inhibitorrelated pneumonitis in patients with advanced cancer a systematic review and meta-analysis. JAMA Oncol . 2016;2(12):1607–16.
Nishijima TF, Shachar SS, Nyrop KA, Muss HB. Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapyin Patients with Advanced Cancer:AMeta-Analysis.Oncologist.2017;22(4):470–9.
Khunger M, Rakshit S, Pasupuleti V, Hernandez AV., Mazzone P, Stevenson J,et al. Incidence of programmed cel l death 1 inhibitor-related pneumonitis in patients with advanced cancer a systematic review and meta-analysis . Oncologist [Internet].2017;157631(4):709–17.Available from:http://dx.doi.org/10.1016/j.chest.2017.04.177
Naidoo J, Wang X, Woo K M, Iyriboz T, HalpennyD, Cunningham J,et al. Pneumonitis in patients treated with antiprogrammed death-1/programmed death ligand 1 therapy. JClin Oncol.2017;35(7):709–17.
Rashdan S, Minna JD, Gerber DE. Diagnosis and management of pulmonary toxicity associated with cancer immunotherapy.The Lancet RespiratoryMedicine.2018.